نتایج جستجو برای: azd1152

تعداد نتایج: 42  

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Robert W Wilkinson Rajesh Odedra Simon P Heaton Stephen R Wedge Nicholas J Keen Claire Crafter John R Foster Madeleine C Brady Alison Bigley Elaine Brown Kate F Byth Nigel C Barrass Kirsten E Mundt Kevin M Foote Nicola M Heron Frederic H Jung Andrew A Mortlock F Thomas Boyle Stephen Green

PURPOSE In the current study, we examined the in vivo effects of AZD1152, a novel and specific inhibitor of Aurora kinase activity (with selectivity for Aurora B). EXPERIMENTAL DESIGN The pharmacodynamic effects and efficacy of AZD1152 were determined in a panel of human tumor xenograft models. AZD1152 was dosed via several parenteral (s.c. osmotic mini-pump, i.p., and i.v.) routes. RESULTS...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2011
D S Boss P O Witteveen J van der Sar M P Lolkema E E Voest P K Stockman O Ataman D Wilson S Das J H Schellens

BACKGROUND To determine, for each of two dosing schedules, the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of AZD1152, an Aurora B kinase inhibitor, and to evaluate its safety, biologic activity and pharmacokinetics (PK). PATIENTS AND METHODS Patients with advanced solid malignancies were treated with escalating doses (100-650 mg) of AZD1152, administered as a 2-h infusion e...

Journal: :Molecular cancer therapeutics 2010
Martin Grundy Claire Seedhouse Shilli Shang Jaineeta Richardson Nigel Russell Monica Pallis

Aurora kinases play an essential role in orchestrating chromosome alignment, segregation, and cytokinesis during mitotic progression and both aurora-A and B are frequently overexpressed in a variety of human malignancies. In this study, we report the effects of AZD1152-HQPA, a highly selective inhibitor of aurora-B kinase, in acute myeloid leukemia (AML) cell lines and primary samples. We show ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2009
Jayasree S Nair Elisa de Stanchina Gary K Schwartz

PURPOSE AZD1152 is an Aurora B kinase inhibitor currently in clinical trials. As the topoisomerase I poison CPT-11 induces a G(2) arrest, a mechanistic understanding of the cell cycle interactions between these agents may prove critical for combination therapy. METHODS AZD1152 was tested in vitro and in vivo with SN-38 and CPT-11 against HCT-116 cells. Inhibition of clonogenicity, induction o...

Journal: :Blood 2007
Jing Yang Takayuki Ikezoe Chie Nishioka Taizo Tasaka Ayuko Taniguchi Yoshio Kuwayama Naoki Komatsu Kentaro Bandobashi Kazuto Togitani H Phillip Koeffler Hirokuni Taguchi Akihito Yokoyama

Aurora kinases play an important role in chromosome alignment, segregation, and cytokinesis during mitosis. We have recently shown that hematopoietic malignant cells including those from acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) aberrantly expressed Aurora A and B kinases, and ZM447439, a potent inhibitor of Aurora kinases, effectively induced growth arrest and apoptos...

Journal: :Cancer research 2009
Adedayo Oke Daniel Pearce Robert W Wilkinson Claire Crafter Rajesh Odedra Jamie Cavenagh Jude Fitzgibbon Andrew T Lister Simon Joel Dominique Bonnet

Aurora kinases play a critical role in regulating mitosis and cell division, and their overexpression has been implicated in the survival and proliferation of human cancer. In this study, we report the in vitro and in vivo activities of AZD1152, a compound that has selectivity for aurora B kinase, in acute myeloid leukemia (AML) cell lines, primary AML samples, and cord blood cells. AZD1152 exe...

Journal: :Endocrine-related cancer 2011
Silvana Libertini Antonella Abagnale Carmela Passaro Ginevra Botta Sara Barbato Paolo Chieffi Giuseppe Portella

Novel therapeutic approaches are required for the treatment of anaplastic thyroid carcinoma (ATC), an incurable disease resistant to current available therapies. Aurora B is an important mitotic kinase involved in chromosome segregation and cytokinesis. It is overexpressed in many cancers including ATC and represents a potential target for chemotherapy. The effects of AZD1152, a specific Aurora...

2013
Claire M Cannon John Pozniak Milcah C Scott Daisuke Ito Brandi H Gorden Ashley J Graef Jaime F Modiano

We evaluated the effect of Aurora kinase inhibitors AZD1152 and VX680 on canine osteosarcoma cells. Cytotoxicity was seen in all four cell lines; however, half-maximal inhibitory concentrations were significantly higher than in human leukaemia and canine lymphoma cells. AZD1152 reduced Aurora kinase B phosphorylation, indicating resistance was not because of failure of target recognition. Efflu...

Journal: :Molecular cancer therapeutics 2008
Jeffrey Cummings Cassandra Hodgkinson Rajesh Odedra Patrizia Sini Simon P Heaton Kirsten E Mundt Tim H Ward Robert W Wilkinson Jim Growcott Andrew Hughes Caroline Dive

M30 and M65 are ELISAs that detect different circulating forms of cytokeratin 18. Using the aurora kinase inhibitor AZD1152 and the SW620 human colon cancer xenograft, experiments were conducted to qualify preclinically both assays as serologic biomarkers of cell death. Using two different apoptotic markers, the kinetics of cell death induced by AZD1152 was first characterized in vitro in three...

ژورنال: پیاورد سلامت 2013
ذاکر, فرهاد, ذکری, علی, علی مقدم, کامران, غفاری, سید حمیدالله , غنی زاده وصالی, صمد, قوام زاده, اردشیر,

 Background and Aim: A goal of modern cancer research is to reach targeted therapies with drugs having fewer side effects. AZD1152 is a highly specific inhibitor of Aurora Kinase B, which leads to the programmed cell death by different mechanisms. The aim of this study was to evaluate the effects of AZD1152 on viability and metabolic activity of NB4 cells (APL derived cell line).  Materials and...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید